Clinical Trials Logo

Clinical Trial Summary

The Relaxation Response Resiliency Program (3RP) has shown efficacy in improving coping and resilience across diverse populations; however, little is known about how it helps individuals manage the challenges of living with a chronic illness. This study proposes to pilot test an adapted version of the 3RP among patients living with VHL.


Clinical Trial Description

The 3RP has not been carried out with VHL patients. As such, the investigators are looking to see if an adapted program, tailored to the needs of patients with VHL, is feasible, acceptable, and helpful in improving coping among individuals living with VHL. This study is a two phase trial. Phase I is descriptive. It is comprised of conducting interviews with patients and caregivers to understand the challenges of living with VHL and patient's programatic needs. This information will be used to tailor the program for patients living with VHL. Phase II is a single-arm feasibility trial that will examine if the adapted program is feasible, acceptable, and helps promote stress management among VHL patients. To these means, we will test the adapted 3RP (3RP-VHL) in up to 40 patients living with VHL. Participants will complete surveys at baseline and post 3RP-VHL program completion. This record will reflect the trial component (Phase II) only, as feasibility and acceptability outcomes will be collected for this phase. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05737602
Study type Interventional
Source Massachusetts General Hospital
Contact Giselle Perez, PhD
Phone (617) 724-0287
Email Gperez@mgh.harvard.edu
Status Recruiting
Phase N/A
Start date July 1, 2024
Completion date July 1, 2025

See also
  Status Clinical Trial Phase
Completed NCT01734486 - Growth Response in Girls With Turner Syndrome Phase 4
Completed NCT01529944 - Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658 Phase 3
Completed NCT01518036 - Use of Somatropin in Turner Syndrome Phase 3
Completed NCT00025870 - Studies of Children With Metabolic and Other Genetic Disorders
Completed NCT01563926 - Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Phase 3
Active, not recruiting NCT01851447 - Skeletal Muscle Biomarkers in People With Fragile Sarcolemmal Muscular Dystrophy
Completed NCT01435629 - A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin N/A
Completed NCT01245374 - Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Phase 4
Terminated NCT01135537 - Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants Phase 2
Completed NCT00705172 - Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome
Completed NCT01518062 - Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome Phase 4
Recruiting NCT02769949 - Pediatric Patients With Metabolic or Other Genetic Disorders
Terminated NCT00358657 - Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders Phase 2
Completed NCT01604161 - Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome N/A
Completed NCT01516229 - Special Survey for Long Term Application N/A
Recruiting NCT03093220 - Molecular Typing of Community-acquired Pneumonia Based on Multiple-omic Data Analysis N/A
Enrolling by invitation NCT04681781 - SLC13A5 Deficiency Natural History Study - Remote Only
Completed NCT01529840 - Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome Phase 3
Completed NCT01710696 - Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome Phase 3
Completed NCT01401244 - Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers Phase 1